Hill September 29, 2023
Joseph Choi

The deadline for drugmakers to sign agreements to negotiate with Medicare on pricing is fast approaching. Major drugmakers have until Sunday to sign an agreement to participate in the program or potentially face heavy taxes and lose their ability to sell through Medicare.

With courts yet to impose an injunction in a spate of pending lawsuits, several of the companies producing the 10 drugs selected for Medicare negotiations appear ready to move ahead with negotiations.

Merck, whose diabetes treatment Januvia was selected, made it known it will sign an agreement with the Centers for Medicare & Medicaid Services (CMS) “under protest.”

“While we disagree on both legal and policy grounds with the IRA’s new program, withdrawing all of the company’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article